Panobinostat (LBH589)

Catalog No.S1030 Synonyms: NVP-LBH589

Panobinostat (LBH589) Chemical Structure

Molecular Weight(MW): 349.43

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

Size Price Stock Quantity  
USD 90 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 52 Publications

12 Customer Reviews

  • (G) A375 parental and BRAFi-resistant ex vivo clones were treated with a panel of HDACi (1 μM vorinostat, 0.5 μM belinostat, and 6 nM panobinostat) in single treatment or in combination with 1 μM vemurafenib in a long-term colony formation assay.

    Cell, 2018, 173(6):1413-1425. Panobinostat (LBH589) purchased from Selleck.

    LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Panobinostat (LBH589) purchased from Selleck.

  • Using CRISPR-Cas9 technology, ERα was silenced at the genomic level in ECC1 cells. Ishikawa, parental ECC1 cells and individual ESR1 KO ECC1 clones were treated with 20 nM LBH589 for 24 hr. Expression of ERα, PR, FOXO1, and Myc were evaluated by Western blotting. β-actin serves as a loading control.

    PLoS One, 2016, 11(2):e0148912.. Panobinostat (LBH589) purchased from Selleck.

    HDACIs That Simultaneously Inhibit HDACs 1 and 6 Showed Greater Antileukemic Activities than HDACIs that Don’t at Cmax Concentrations. THP-1 cells were treated with LBH-589, PXD101, SAHA, VPA, MS-275 and MGCD0103 at Cmax concentrations for 3 h and 24 h, respectively. The cells post 3 h treatments were washed three times with complete medium and divided into two halves. One half of the cells was resuspended in complete media and cultured for up to 24 h to determine the effects of the 3 h treatments on cell proliferation and apoptosis. The other half of the cells was used to prepare whole cell lysates. Whole cell lysates from the 3 h and 24 h treatments were extracted and subjected to Western blots probed by anti-ac-tubulin or –b-actin antibody (panels A&B), or subjected to HDAC1 enzymatic assays post IP as described in the Materials and Methods (Panels C&D). The effects of the 3 h and 24 h HDACI treatments on cell proliferation, as reflected by percent decrease of live cells relative to untreated cells (panel E), and apoptosis (panel F) were determined by flow cytometry analysis as described in the Materials and Methods.

     

     

    PLoS One 2011 6, e17138. Panobinostat (LBH589) purchased from Selleck.

  • Induction of DNA Damage and Bim Is Critical for HDACI-Induced Apoptosis in Pediatric AML Cells. THP-1 cells were treated with the HDACIs at Cmax concentrations for 3 (panel A) and 24 h (panel B), respectively. Whole cell lysates were extracted and subjected to Western blots probed by anti-p21, -c-Myc, -cH2AX, -Bim, or -b-actin antibody.

     

     

    PLoS One 2011 6, e17138. Panobinostat (LBH589) purchased from Selleck.

    Cell death induction by LBH589 as a single agent was detected in control or MTDH knockdown Hec50co cells. After 3 days, cell death was determined by the WST-1 method.

    PLoS One 2011 6, e20920. Panobinostat (LBH589) purchased from Selleck.

  • Expression of pro-/anti-apoptosis genes. Control or MTDH knockdown Hec50co cells were treated for 24 hours with vehicle control, 20 nM LBH589, 25 ng/ml TRAIL or LBH589 and TRAIL at the concentrations noted. Lysates were collected. Expression of DR4, DR5, and apoptosis related caspase-3, caspase-8, PARP-1, BID, FLIP, XIAP, Bim, MCL-1 and BCL-XL was analyzed by Western blotting.

    PLoS One 2011 6, e20920. Panobinostat (LBH589) purchased from Selleck.

    p53(+/+) and (/) HCT116 cells were treated with TSA (1–5 lM),LBH589 (2–5 lM), valproate (2.5–5 mM), MS-275 (20 lM) and sodium butyrate (2 mM). TAp63 expression was compared in both cell lines after 24 h of treatment. Consistent with the above data, all HDAC inhibitors failed to induce significant levels of TAp63 in p53(/) HCT116 cells.

     

     

    Biochem Bioph Res Co 2009 391, 1748-1751. Panobinostat (LBH589) purchased from Selleck.

  • Effect of panobinostat on the viability of cervical cancer cells. HeLa (A) and SiHa (B) cells were treated with increasing concentrations of panobinostat for 24, 48 and 72 h. Cell viability was determined by MTT assay. The results are presented as percentage; calculated from the reduction in cell viability at a given concentration of drug compared to the untreated control (untreated control being 100%). The IC5072h values were calculated from sigmoidal dose-response curves generated in Prism 5.0 (GraphPad). (C) Cytotoxic effects of panobinostat on HeLa and SiHa cells measured at 72 h and expressed as% cell death. Each value is the mean ± SD of three independent experiments performed in triplicates.

    Biomed Pharmacother, 2016, 84:1393-1405. Panobinostat (LBH589) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-10μM Panobinostat was added.

    Dr.Zhang of Tianjin Medical University. Panobinostat (LBH589) purchased from Selleck.

  • HDAC inhibitors induce p63a expression (A) HCT116 cells were treated with TSA (1 lM), LBH589 (2 lM), valproate (2.5 mM), MS-275 (20 lM) and sodium butyrate(2 mM) for 24 h. Expression of p63 was assessed by Western blotting with the H129 pan-anti-p63 antibody. Although TSA and LBH589 induced p63 efficiently, valproate, MS-275 and sodium butyrate were much less efficient. The lower panel shows the actin loading control. Arrow indicates TAp63. (B) The HDAC inhibitors used in this study are shown, grouped according to their structure and with their HDAC specificity. The efficiency of TAp63 expression is shown in the last column.

     

     

    Dr. Berna S. Sayan of Leicester University. Panobinostat (LBH589) purchased from Selleck.

    U266 and KMS-11 were treated with 20 nM panobinostat for 48 h followed by Western blot analysis. Actin served as a loading control. Nine (U266) and 3 (KMS-11) biologically independent experiments were performed. To determine the expression of PPP3CA mRNA in treated cells for 24 h, we performed relative quantification real-time PCR (n = 6). Four (U266) and 2 (KMS-11) biologically independent experiments were performed.

    JCI Insight, 2016, 1(5):e85061. Panobinostat (LBH589) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
Targets
HDAC (MOLT-4 cells) [1] HDAC (Reh cells) [1]
5 nM 20 nM
In vitro

LBH589 induces apoptosis among MOLT-4 and Reh cells in a time- and dose-dependent manner. Moreover, LBH589 is more potent in MOLT-4 than in Reh cells. LBH589 markedly prevents the growth of both MOLT-4 and Reh cells in a dose-dependent manner at 48 hours. LBH589 treatment causes a 2- to 3-fold increase in the number of cells in the G2/M phase of the cell cycle compared with the control cells. LBH589 is associated with induction of histone H3K9 and histone H4K8 acetylation as well as decreasing levels of c-Myc expression in a dose-dependent manner. LBH589 treatment also increases the levels of p21 expression. LBH589 treatment also decreases the levels of c-Myc after an initial increase at the lowest dose (10 nM) in Reh cells. In addition, LBH589 gives rise to substantial increases in mRNA levels of proapoptosis and DNA repair genes. LBH589 induces increased levels of acetylated histone H3 and H4 at the GADD45G promoter. [1] Besides, LBH589 inhibits growth of non small cell lung cancer cell lines (such as human H1299, L55 and A549 with IC50 of 5 nM, 11 nM and 30 nM, respectively), mesothelioma (such as human OK-6 and Ok-5 with IC50 of 5 nM and 7 nM, respectively) and small cell lung cancer cell lines (such as human RG-1 and LD-T with IC50 of 4 nM and 5 nM, respectively). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT29 NEOzXlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXOwMVExKM7:TR?= MXqwMVQh\A>? Mk\rbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M33mS|I3PzB{N{i0
HepG2 NHGyb4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFewOXkxNTFyIN88US=> NV3OVJdzOC12IHS= NUDTWnFScW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NV\MZooxOjZ5MEK3PFQ>
HT29 MnXGSpVv[3Srb36gRZN{[Xl? NXX0cGRbPTEEoH7N MViyOE04OiCq M2i2Uolv\HWlZXSgZYN1cX[jdHnvckBw\iClYYPwZZNmKDNiYX\0[ZIhPDkEoHlCpC=> M37jR|I3PzB{N{i0
HepG2 NUT1UHV3TnWwY4Tpc44hSXO|YYm= NFv6[Gw2OMLibl2= NUexN2hDOjRvN{KgbC=> M3T6eolv\HWlZXSgZYN1cX[jdHnvckBw\iClYYPwZZNmKDNiYX\0[ZIhOjUEoHlCpC=> MUOyOlcxOjd6NB?=
HCC827 M2D0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrxOU84NjVxMUCgcm0> NXzhOHB5PzMEoHi= MUHEUXNQ M2jKV4VvcGGwY3XzJJRp\SCjboTpdJJwdGmoZYLheIl3\SCnZn\lZ5Qhd2ZiZYLsc5Rqdmmk M2DXbFI3Pjd3NEi0
A549  MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTNXZcyOC9zNT:yNEBvVQ>? NVnpeWRXPzMEoHi= MVjEUXNQ NEDGSHBmdmijbnPld{B1cGViYX70bZBzd2yrZnXyZZRqfmViZX\m[YN1KG:oIHXycI91cW6rYh?= MmTJNlY3PzV2OES=
NCI-H460  M{DZT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2f3TVExNzJyL{OwJI5O M{Pa[VczyqCq MYTEUXNQ NF7qVmxmdmijbnPld{B1cGViYX70bZBzd2yrZnXyZZRqfmViZX\m[YN1KG:oIHXycI91cW6rYh?= MknLNlY3PzV2OES=
J89GFP MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LjdWROW00EoB?= MWDFR|UxRTR7Lki1JOKyKDF{Lk[1JI5O M4KwblI3PTZ|NU[4
THP89GFP NFTjUVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPwSG1UV8Li NXX2Z5k6TUN3ME2xPU4{PCEEsTC2MlQ{KG6P NWS3e3VXOjZ3NkO1Olg>
SK-NEP-1 NIfuU|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVK0VVVFOC5yMfMAl|ExNjBizszN M3HsdlI1KGh? Ml[wSG1UV8Li NF23Z25KSzVyPUe2MlM1KG6P NVjn[4xWOjZzN{[yNVk>
G401 M{\TWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TsdlAvODIkgKOxNE4xKM7:TR?= NUDmd5J[OjRiaB?= MUnEUXNQyqB? NEDCXmNKSzVyPUG0N{4xOiCwTR?= NFSx[4ozPjF5NkKxPS=>
SK-NEP-1 MmLyR4VtdCCYaXHibYxqfHliQYPzZZk> MlPQOVAhdk1? MkLpNgKBmzRiZB?= MU\EUXNQyqB? MVLy[YR2[2W|IHPlcIwhe3W{dnn2ZYwhcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> MVmyOlE4PjJzOR?=
G401 NVvrVXFKS2WubDDWbYFjcWyrdImgRZN{[Xl? MoDGOVAhdk1? MlLnNgKBmzRiZB?= M{KySmROW00EoB?= NGnEdlFz\WS3Y3XzJINmdGxic4Xyeol3[WxiaX6gZUB1cW2nIHTldIVv\GWwdDDtZY5v\XJ? MlThNlYyPzZ{MUm=
SK-NEP-1 M1zFU2Fxd3C2b4Ppd{BCe3OjeR?= NV\MWWxpPTBxMUCwJI5O MYqyOEBp Moi5SG1UV8Li MVTpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M3Xu[|I3OTd4MkG5
G401 MlTqRZBweHSxc3nzJGF{e2G7 NGi5WVU2OC9zMECgcm0> NI\uSHkzPCCq M1XVbGROW00EoB?= NV34cZZXcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NUnx[|ZWOjZzN{[yNVk>
SK-NEP-1 NEf1e2lHfW6ldHnvckBCe3OjeR?= NVOzTFI1PTBxMUCwJI5O MWCyOEBp NELEeWlFVVORwrC= NV;MbXpMe2ixd4OgeIhmKGmwZIXjeIlwdiCxZjDEUmEh\nKjZ33lcpRifGmxbh?= Ml76NlYyPzZ{MUm=
G401 MWTGeY5kfGmxbjDBd5NigQ>? M2Ozc|UxNzFyMDDuUS=> Mnr2NlQhcA>? NHfKO3JFVVORwrC= MmG5d4hwf3NidHjlJIlv\HWldHnvckBw\iCGTlGg[pJi\22nboTheIlwdg>? MU[yOlE4PjJzOR?=
SK-NEP-1 MkS1SpVv[3Srb36gRZN{[Xl? MX61NE8yODBibl2= M{ft[|I1KGh? NXjScGxETE2VT9Mg MkTTbY5lfWOnczDj[YxtKGO7Y3zlJIRqe2:{ZHXyxsA> MUiyOlE4PjJzOR?=
G401 M{HjcGZ2dmO2aX;uJGF{e2G7 MlTwOVAwOTByIH7N M2jjOVI1KGh? MYfEUXNQyqB? NV3tS45qcW6mdXPld{Bk\WyuIHP5Z4xmKGSrc3;y[IVzyqB? Mn7iNlYyPzZ{MUm=
RPMI 8226 MYLD[YxtKFO3co\peoFtKEG|c3H5 MXeyM|QwPiCwTR?= MUS0PQKBkWh? M3PxUolv\HWlZYOgZUB{cWewaX\pZ4FvfCCmZXPy[YF{\SCrbjD0bIUh[2WubDDndo94fGh? NVXxNoc5OjZyMECyPVI>
OPM2 NGnmZYNE\WyuIGP1dpZqfmGuIFHzd4F6 MnHONk81NzZibl2= NVf4Z2NCPDkkgJno MmDhbY5lfWOnczDhJJNq\26rZnnjZY51KGSnY4LlZZNmKGmwIITo[UBk\WyuIHfyc5d1cA>? NXHMfYd[OjZyMECyPVI>
U266 M1r1NGNmdGxiU4Xyeol3[WxiQYPzZZk> NUTVWIp7Oi92L{[gcm0> NXrCOFR1PDkkgJno NVr3U|J3cW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?= MVqyOlAxODJ7Mh?=
H929 M4DvVGNmdGxiU4Xyeol3[WxiQYPzZZk> NH\FVZYzNzRxNjDuUS=> NGjIcWs1QOLCiXi= NG\aOZNqdmS3Y3XzJIEhe2mpbnnmbYNidnRiZHXjdoVie2ViaX6geIhmKGOnbHyg[5Jwf3Sq MnHSNlYxODB{OUK=
RPMI 8226  NFfUbYFCeG:ydH;zbZMhSXO|YYm= MWi05qCKdk1? M3K5fVI1NzR6IHi= MlnxbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? M3\PV|I3ODByMkmy
HCC827 M2PkbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2f6W|ExKG6P M3rJNlQ5KGh? NX\jemNKTE2VTx?= NVXVTY12\W6qYX7j[ZMh[2m|cHzheIlvKHOnboPpeIl3cXS7wrC= M3PlVlI2QTR2NkG3
NCI-H23 NH7ObldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo[wNVAhdk1? NGXaNVU1QCCq NVznSVFyTE2VTx?= M1rqe4VvcGGwY3XzJINqe3CuYYTpckB{\W6|aYTpeol1gcLi NX[3fYNQOjV7NES2NVc>
AML3 NHX4Z4xHfW6ldHnvckBCe3OjeR?= Mly3NE0yKM7:TR?= NET4S|UzPMLiaB?= M1nzb4lv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MnvENlU3OTJ7NEG=
ML-1 M2Lyb2Z2dmO2aX;uJGF{e2G7 MUmwMVEh|ryP MYGyOOKhcA>? MVTpcoR2[2W|IFTORUBnemGpbXXueIF1cW:wwrDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MUWyOVYyOjl2MR?=
RPMI-8226vr10  MUDGeY5kfGmxbjDBd5NigQ>? NV7QTGpmOC1zIN88US=> MWeyOOKhcA>? NITqfJNqdmS3Y3XzJGRPSSCocnHncYVvfGG2aX;uxsBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NWT6VnNXOjV4MUK5OFE>
ML-1 MnXISpVv[3Srb36gRZN{[Xl? MoXJNUDPxE1? NU\TR21{OjUEoHi= MVrpcoNz\WG|ZYOgZ4F{eGG|ZT2zJIFkfGm4aYT5JFQu\m:uZB?= MnHXNlU3OTJ7NEG=
RPMI-8226vr10  M3z3N2Z2dmO2aX;uJGF{e2G7 MoHoNUDPxE1? MojENlTDqGh? M2nMRolv[3KnYYPld{Bk[XOyYYPlMVMh[WO2aY\peJkhOi53LX\vcIQ> MlvhNlU3OTJ7NEG=
SK-N-BE (2) M2jofWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYqyOQKBkWh? NF7qTW9KSzVyPUGwOE4x6oDLwsJihKk4Njhibl2= MXSyOVMxQDlzNh?=
SK-N-BE (2), PAN  MK NI\FeWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PxO|I16oDLaB?= MmHQTWM2OD1zMESuNQKBkcLz4pEJO{45KG6P NELXOW4zPTNyOEmxOi=>
SK-N-BE (2), MK  PAN MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXuyOQKBkWh? MlrNTWM2OD1|OEKuNQKBkcLz4pEJOFMvOiCwTR?= M1zYUVI2OzB6OUG2
SK-N-AS NHLHUnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vrZlI16oDLaB?= MYDJR|UxRTN5LkJihKnDueLCiUKuOEBvVQ>? NUe4S5AyOjV|MEi5NVY>
SK-N-DZ MlPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITsbZYzPOLCiXi= M2O1WGlEPTB;MUeuNgKBkcLz4pEJNE41KG6P NEDsPY0zPTNyOEmxOi=>
Caki-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1r6OlExNzJ3L{WwJI5O Mnz2OFghcA>? NEn3UnJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= Mm\GNlUzPzlzOUG=
ACHN MmPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDnNVAwOjVxNUCgcm0> NFXIV2Q1QCCq M3LST4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIILpeI9v[X[rch?= NF7EdmUzPTJ5OUG5NS=>
769-P MknmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHX4S|IyOC9{NT:1NEBvVQ>? MX60PEBp M1zpb4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIILpeI9v[X[rch?= M{XCcVI2Ojd7MUmx
786-O  NETXWG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUmxNE8zPS93MDDuUS=> Mn;2OFghcA>? NX\XepdPcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigdol1d26jdnny NXvWWlhPOjV{N{mxPVE>
Caki-1 MlXoRZBweHSxc3nzJGF{e2G7 M3WzT|UxKG6P NFvxfpQ1QCCq MYHpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGOxbXLpcoVlKHKrdH;uZZZqeg>? MVOyOVI4QTF7MR?=
ACHN MlXZRZBweHSxc3nzJGF{e2G7 M2mxV|UxKG6P NIfoXWU1QCCq NIfKeFFqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHPvcYJqdmWmIILpeI9v[X[rch?= MmPtNlUzPzlzOUG=
769-P MoWwRZBweHSxc3nzJGF{e2G7 Mn3XOVAhdk1? M4T0TlQ5KGh? NHjQcHpqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHPvcYJqdmWmIILpeI9v[X[rch?= NGnHU2czPTJ5OUG5NS=>
786-O  M{fy[WFxd3C2b4Ppd{BCe3OjeR?= MlqzOVAhdk1? NH;4VHg1QCCq NYHRU4RbcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDjc41jcW6nZDDybZRwdmG4aYK= Ml7zNlUzPzlzOUG=
Caki-1 MnrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnjNlUwPTBibl2= M3TGWVQ5KGh? MkHZSG1UVw>? M13NU4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIHLvdpRmgm:vaXK= MlXKNlUyPzZ|NUS=
ACHN NF;kbHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXKVmQzPS93MDDuUS=> M3XXRVQ5KGh? NES1fGJFVVOR NWHWXWVwcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigZo9zfGW8b33pZi=> NWf2NFltOjVzN{[zOVQ>
769-P NIntNHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moq3NlUwPTBibl2= NG\i[VE1QCCq NHLwU|ZFVVOR MYfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCCkb4L0[ZpwdWmk MnvONlUyPzZ|NUS=
Caki-1 MVfDc4xwdnliRn;ycYF1cW:wIFHzd4F6 M2TGS|UxKG6P MkT2O{0yPCCm MlnaSG1UVw>? M4[yS5N2eHC{ZYPz[YQh[2:ub375JIZwem2jdHnvckB{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghf2m2aDDic5J1\XqxbXniJOKh NEPZOlEzPTF5NkO1OC=>
ACHN NIDMVlJEd2yxbomgSo9zdWG2aX;uJGF{e2G7 MonWOVAhdk1? Mly1O{0yPCCm NGrS[lZFVVOR NELsOnZ{fXCycnXzd4VlKGOxbH;ufUBnd3KvYYTpc44he2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKHerdHigZo9zfGW8b33pZkDDqA>? NEPYXWwzPTF5NkO1OC=>
769-P MVTDc4xwdnliRn;ycYF1cW:wIFHzd4F6 MY[1NEBvVQ>? NWHmdFAzPy1zNDDk MnjZSG1UVw>? NUfhfVFWe3WycILld5Nm\CClb3zvcpkh\m:{bXH0bY9vKHOrZ37p[olk[W62bImgZ49u[mmwZXSge4l1cCC5aYToJIJwenSnen;tbYIhyqB? MnuwNlUyPzZ|NUS=
Caki-1 MlvtRZBweHSxc3nzJGF{e2G7 NG\GZ3M2OCCwTR?= M{Pj[VQ5KGh? MlOwSG1UVw>? MoLWbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NUPreolTOjVzN{[zOVQ>
ACHN NIm3V2hCeG:ydH;zbZMhSXO|YYm= MYi1NEBvVQ>? MVG0PEBp MmC2SG1UVw>? MU\pcoR2[2W|IHPlcIwh[XCxcITvd4l{ M37KPFI2OTd4M{W0
769-P NGP3OmxCeG:ydH;zbZMhSXO|YYm= MX61NEBvVQ>? MoThOFghcA>? NWnRVG95TE2VTx?= M3K5eYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MXeyOVE4PjN3NB?=
MDA-MB-231 NW\KWll5VW:{cHjvcI9ocWOjbDDDdpl{fGGuIG\pc4xmfCBqQ2[pJGF{e2G7 NY\CbWdUOTEEoH7N Mn7NN:Kh\A>? MkfFSG1UVw>? M3rrV4FtfGW{czDj[YxtKG2xcoDoc4xw\3oEoB?= MkXqNlQ5OTB2OUe=
BT-549 NWjDdlhyVW:{cHjvcI9ocWOjbDDDdpl{fGGuIG\pc4xmfCBqQ2[pJGF{e2G7 NUDxbpZQOTEEoH7N M161SFPDqGR? NXPKN|U3TE2VTx?= NWPTT4l3[Wy2ZYLzJINmdGxibX;ydIhwdG:pedMg NU\MOY9vOjR6MUC0PVc>
MCF-7  NWSzbmdyVW:{cHjvcI9ocWOjbDDDdpl{fGGuIG\pc4xmfCBqQ2[pJGF{e2G7 NWHiSI1wOTEEoH7N NF3jcFQ{yqCm M2CxOGROW09? M1TySYFtfGW{czDj[YxtKG2xcoDoc4xw\3oEoB?= NYXTOlFvOjR6MUC0PVc>
MCF-7 Mo[4SpVv[3Srb36gRZN{[Xl? M{PtOlUuPTBibl2= MU[yOEBp NUexOmM1TE2VTx?= M2jJS5Jm\HWlZXSgeIhmKGyndnXsJI9nKGW6cILld5Nqd25ib3[gSXLPuSxiUGKgZY5lKE[xeFGxxsA> MVOyOFM3PjRyNx?=
CTS NF\OR4pCeG:ydH;zbZMhSXO|YYm= NFH0XVEx6oDVNECgcm3DqA>? MoHzOFghcA>? NXvGR5J5cW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NHLJb2IzPDJ2NESyPS=>
OCI-AML3  M3\INmFxd3C2b4Ppd{BCe3OjeR?= Ml32NQKBmzRyIH7NxsA> M3u1O|Q5KGh? M1rKbIlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NFSzO3IzPDJ2NESyPS=>
U937 NW\n[ZFXSXCxcITvd4l{KEG|c3H5 MmjkNQKBmzRyIH7NxsA> NVXr[2tbPDhiaB?= Mle5bY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NYfOW5QyOjR{NES0Nlk>
PC3 M4\TdmFxd3C2b4Ppd{BCe3OjeR?= M{Cz[VAuOTByIH7N M4\oZVI1NzR6IHi= MVnpcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M4Sw[FI1OTZ|MkOw
PC3-AR MlnERZBweHSxc3nzJGF{e2G7 NVGyd|RUOC1zMECgcm0> NFn1cXMzPC92ODDo MkjMbY5lfWOnczDhdI9xfG:|aYOgbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S2mZYDlcoRmdnRibXHucoVz NHWwbGozPDF4M{KzNC=>
PC3 MmqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TwR|AuOTByIH7N MmSwNlQwPDhiaB?= NUjX[I5OcW6mdXPld{Bi[2O3bYXsZZRqd25ib3[gd5VjTzFicH;weYxifGmxbh?= MlixNlQyPjN{M{C=
PC3-AR M4jVTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWewMVExOCCwTR?= MUKyOE81QCCq M2jlV4lv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgbY4hfGinIFeyUUBxcGG|ZR?= NIXKOXczPDF4M{KzNC=>
PC3 M3LjO2Z2dmO2aX;uJGF{e2G7 Mon0NE0yODBibl2= MmDLNlQhcA>? Mmn1d5VxeHKnc4Pld{BmgHC{ZYPzbY9vKG:oIHHjeIl3[XSnZDDBWG0tKEGtdDDhcoQhTXKtMT:yJJBzd3SnaX6= NFmzbG8zPDF4M{KzNC=>
PC3-AR MlTrSpVv[3Srb36gRZN{[Xl? NILqXncxNTFyMDDuUS=> NEPOOVczPCCq MVTzeZBxemW|c3XzJIV5eHKnc4Ppc44hd2ZiYXP0bZZifGWmIFHUUUwhSWu2IHHu[EBGemtzL{KgdJJwfGWrbh?= NUDmWo42OjRzNkOyN|A>
OS-RC-2 MoXNR4VtdCCYaXHibYxqfHliQYPzZZk> M33vVVAuOTByMDDuUS=> MYKyOE81QC95MjDo NUXTT|hMTE2VTx?= M4HodoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MU[yOFE1PDd|Nx?=
OS-RC-2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHOO3c2OCCwTR?= MmPCOFghcA>? MXfEUXNQ MnHkbY5lfWOnczDHNk9OKGG{cnXzeC=> MnrQNlQyPDR5M{e=
OS-RC-2 M1;DbmFxd3C2b4Ppd{BCe3OjeR?= NHjmVmk2OCCwTR?= Mo\NOFghcA>? M{jHTGROW09? MU\pcoR2[2W|IHPlcIwh[XCxcITvd4l{ NFXseYQzPDF2NEezOy=>
SK-N-AS MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXtNVhoOOLCk{iwJI5O NXXYOlhRPDhiaB?= NGjiTIlKSzVyPUK3MlQhdk1? MXuyOFA6QDd7OR?=
SK-N-DZ NUDhO2dLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHGNWlIOOLCk{iwJI5O MmLXOFghcA>? M3vO[WlEPTB;MkGuPUBvVQ>? MmK5NlQxQTh5OUm=
SK-N-SH NHTHNYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPUXFAx6oDVOECgcm0> M2C0elQ5KGh? NX7XZ|lrUUN3ME23Nk4{KG6P MYmyOFA6QDd7OR?=
SK-N-BE NFPnc5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoW3NQKBmzhyIH7N MVy0PEBp M3vpZmlEPTB;N{WuOEBvVQ>? M4raOFI1ODl6N{m5
SK-N-AS NGLpNpNCeG:ydH;zbZMhSXO|YYm= NV\ac3RsOOLCk{iwJI5O Mn3YOFghcA>? NWHmTmV4eG:2ZX70cJkhcW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCoYYPobY9v Mm[3NlQxQTh5OUm=
SK-N-DZ NVTld|V1SXCxcITvd4l{KEG|c3H5 NX7HR3R3OOLCk{iwJI5O NVqzNpdKPDhiaB?= NVHsNW5IeG:2ZX70cJkhcW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCoYYPobY9v MWOyOFA6QDd7OR?=
SK-N-SH NFvwOnpCeG:ydH;zbZMhSXO|YYm= MlH6NQKBmzRyIH7N M2fS[|Q5KGh? MoD1dI91\W62bImgbY5lfWOnZDDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u NEPuT5EzPDB7OEe5PS=>
SK-N-BE MX\BdI9xfG:|aYOgRZN{[Xl? NVfafXJROOLCk{SwJI5O M1LHblQ5KGh? NX7GWlR2eG:2ZX70cJkhcW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCoYYPobY9v MWOyOFA6QDd7OR?=
SK-N-AS MY\GeY5kfGmxbjDBd5NigQ>? MlzRNQKBmzhyIH7N MWW0PEBp MVTpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiY3zlZZZi\2Vib3[gZ4F{eGG|ZTCzJIFv\CCSQWLQ MnnHNlQxQTh5OUm=
SK-N-DZ M{LycmZ2dmO2aX;uJGF{e2G7 NWDHfGZ[OOLCk{iwJI5O Ml\MOFghcA>? NHLUfmVqdmS3Y3XzJIEh\G:|ZT3k[ZBmdmSnboSgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[UA{KGGwZDDQRXJR NEPzbJYzPDB7OEe5PS=>
SK-N-SH MYrGeY5kfGmxbjDBd5NigQ>? MnXpNQKBmzRyIH7N M1SzflQ5KGh? NYWwflZvcW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>? Ml3JNlQxQTh5OUm=
SK-N-BE MofRSpVv[3Srb36gRZN{[Xl? MUGw5qCUPDBibl2= NEPPdWg1QCCq NXS3TFFUcW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>? M4XzZ|I1ODl6N{m5
HCC-LM3 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDnPFgyNTFyMECgcm0> NXf3VFUyOjRxNEivO|IhcA>? M3PuRWROW09? M{PhZYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NGfVeGwzPDB7M{m1Oi=>
HepG2 NW\oem9HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkCyNU0yODByIH7N MYOyOE81QC95MjDo NWnGWYs4TE2VTx?= NGDCOIdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MUOyOFA6Ozl3Nh?=
SMMC-7721 M1fVN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWeyeWNiOS1zMECwJI5O M3rINVI1NzR6L{eyJIg> MVLEUXNQ M1nHZYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NFu5V4gzPDB7M{m1Oi=>
HCC-LM3 M1q0ZWFxd3C2b4Ppd{BCe3OjeR?= MV61NEBvVQ>? NXzS[I56PDhiaB?= M13ybGROW09? M1faZ4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfUBqdiCjIHPhd5Bie2VvZHXw[Y5l\W62IH3hco5meiCkeTDjcIVifmGpZTDv[kBk[XOyYYPld{A{NCB6IHHu[EA6 Ml2yNlQxQTN7NU[=
HepG2 NUj5PZpISXCxcITvd4l{KEG|c3H5 MYC1NEBvVQ>? NHPJcWg1QCCq M124SWROW09? NXnCeVZ3cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGmwIHGgZ4F{eGG|ZT3k[ZBmdmSnboSgcYFvdmW{IHL5JINt\WG4YXflJI9nKGOjc4Dhd4V{KDNuIEigZY5lKDl? MXGyOFA6Ozl3Nh?=
SMMC-7721 MWPBdI9xfG:|aYOgRZN{[Xl? MnXpOVAhdk1? NV\qUZU4PDhiaB?= NXrvTJhuTE2VTx?= M1jkVIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfUBqdiCjIHPhd5Bie2VvZHXw[Y5l\W62IH3hco5meiCkeTDjcIVifmGpZTDv[kBk[XOyYYPld{A{NCB6IHHu[EA6 NInLTYIzPDB7M{m1Oi=>
HCC-LM3 NViwcllKTnWwY4Tpc44hSXO|YYm= MkD5OVAwOTByIH7N NX[xcXFSOjRiaB?= M2LN[mROW09? MlzU[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZicD3TWGFVOyCjbnSgdE1Cc3UEoB?= MU[yOFA6Ozl3Nh?=
HepG2 Mm\6SpVv[3Srb36gRZN{[Xl? MWm1NE8yODBibl2= Mn\ZNlQhcA>? M1LPfWROW09? MWnk[YNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCyLWPURXQ{KGGwZDDwMWFsfMLi MVqyOFA6Ozl3Nh?=
SMMC-7721 NVjtbYxWTnWwY4Tpc44hSXO|YYm= MlP2OVAwOTByIH7N MUCyOEBp NHTI[5BFVVOR NH;GVXNl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDwMXNVSVR|IHHu[EBxNUGtdNMg M1\SXlI1ODl|OUW2
HCC-LM3 MUDGeY5kfGmxbjDBd5NigQ>? NVHXNnFxPTBxMUCwJI5O NH7TS3QzPCCq M1G0WmROW09? MXLkc5dvemWpdXzheIV{KEKlbD34UEBmgHC{ZYPzbY9v NWS2OGhXOjRyOUO5OVY>
HepG2 NF61[|ZHfW6ldHnvckBCe3OjeR?= M{Du[lUxNzFyMDDuUS=> MojLNlQhcA>? NIWwNpBFVVOR MVHkc5dvemWpdXzheIV{KEKlbD34UEBmgHC{ZYPzbY9v MUGyOFA6Ozl3Nh?=
SMMC-7721 MUHGeY5kfGmxbjDBd5NigQ>? MXi1NE8yODBibl2= MoS1NlQhcA>? M{myb2ROW09? NHPCeoZld3ewcnXneYxifGW|IFLjcE15VCCneIDy[ZN{cW:w Mk[4NlQxQTN7NU[=
FaDu M4f2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXyOHoyODEkgJXuUS=> M4rENlgwOTBxMUKgbC=> MYnkbZNxdGG7ZXSgZUB{cWewaX\pZ4FvfCCjbnSgdJJwdG:wZ3XkJGczN01iYYLy[ZN1KGG2IEigZY5lKDF{4pEFbEBxd3O2IILlcIVie2V? M4r4T|I1ODJ4NEiy
FaDu NISwbpJHfW6ldHnvckBCe3OjeR?= NFnkZoEyODEkgJXuUS=> NEjX[lEzNzRxOD:xNkBp MoTLbY5lfWOnZDDwNlFY[WZzL1PpdFHDqGW6cILld5Nqd25? NETUV4czPDB{NkS4Ni=>
PC-3  MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEn4SpQxNTFyIN88US=> MXKyOE81QC95MjDo NXy4RWtJcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy Mn\UNlM6QTF{MU[=
LNCaP NGmx[mpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYX2UG5VOC13IN88US=> MX[yOE81QC95MjDo MWDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NX\YU45NOjN7OUGyNVY>
RWPE-1  MkThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PX[VAuOjBizszN NF3CRWgzPC92OD:3NkBp NI\2fJhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NFTUdFgzOzl7MUKxOi=>
Capan-1 MnXPSpVv[3Srb36gRZN{[Xl? NIHu[nUzPS93MD:xNFAhdk1? MXi4M|I1NzR6IHi= MnfISG1UVw>? MWHkc5dvemWpdXzheIVlKFKxbjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36gZY5lKGSxd37zeJJm[W1ic3nncoFtcW6p NYHSTGZsOjN7MkK4PFY>
L3.6pl MXPGeY5kfGmxbjDBd5NigQ>? M4\RUFI2NzVyL{GwNEBvVQ>? MmnKPE8zPC92ODDo M1;XPWROW09? M{fwNIRwf26{ZXf1cIF1\WRiUn;uJI1TVkFiYX7kJJBzd3SnaX6g[ZhxemW|c3nvckBidmRiZH;3cpN1emWjbTDzbYdv[Wyrbne= NUDzT2h2OjN7MkK4PFY>
CFPAC-1  MUjGeY5kfGmxbjDBd5NigQ>? NXfkOopVOjVxNUCvNVAxKG6P MlTMPE8zPC92ODDo NYe1PXNWTE2VTx?= NVrXR5o4\G:5boLl[5Vt[XSnZDDSc44hdVKQQTDhcoQheHKxdHXpckBmgHC{ZYPzbY9vKGGwZDDkc5dve3S{ZXHtJJNq\26jbHnu[y=> MWmyN|kzOjh6Nh?=
Capan-1 NWHZR3hvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXeyOU82OC9zMECgcm0> M4Hp[lQ5KGh? MV;EUXNQ MUDy[YR2[2W|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MXeyN|kzOjh6Nh?=
L3.6pl M4C1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PUOlI2NzVyL{GwNEBvVQ>? NFvYbGc1QCCq M4[4e2ROW09? NIj5RYpz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MXyyN|kzOjh6Nh?=
CFPAC-1  M1LqXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;1bFI2NzVyL{GwNEBvVQ>? MUC0PEBp MXHEUXNQ MYfy[YR2[2W|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MkDXNlM6OjJ6OE[=
Capan-1 M2nDcmFxd3C2b4Ppd{BCe3OjeR?= NILxXIkzPS93MD:xNFAhdk1? M1fxTlQ5KGh? MVLEUXNQ M4fLN4lv\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NXXNZ4N2OjN7MkK4PFY>
L3.6pl MkPYRZBweHSxc3nzJGF{e2G7 NF25OJUzPS93MD:xNFAhdk1? NVrxfmxXPDhiaB?= NIP5U2FFVVOR Ml3lbY5lfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MV[yN|kzOjh6Nh?=
CFPAC-1  MVzBdI9xfG:|aYOgRZN{[Xl? NWj0[YV[OjVxNUCvNVAxKG6P NEKyWHQ1QCCq M1\wNmROW09? MX7pcoR2[2W|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NH\C[IkzOzl{Mki4Oi=>
HN22 M{nNZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnENE0zOCCwTR?= NIKwZZMzPC92ODDo MVjEUXNQ MnPGbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lMUBidmRiZH;z[U0h\GWyZX7k[Y51KG2jbn7ldi=> M4jlNFI{QDd5MkO1
HSC4  M{H3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rwbFAuOjBibl2= MV:yOE81QCCq M4HL[WROW09? MmqybY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lMUBidmRiZH;z[U0h\GWyZX7k[Y51KG2jbn7ldi=> NH7zOGczOzh5N{KzOS=>
HN22 M4T5OGFxd3C2b4Ppd{BCe3OjeR?= NWrMdIZ7OC1{MDDuUS=> NILjVoc1QCCq M3K4[mROW09? Mm\ZbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MlWxNlM5Pzd{M{W=
HSC4  NELRc|RCeG:ydH;zbZMhSXO|YYm= MWKwMVIxKG6P M1zpXlQ5KGh? NVHLZXpHTE2VTx?= NH7rTW5qdmS3Y3XzJINmdGxiYYDvdJRwe2m| NXTkSoVSOjN6N{eyN|U>
HN22 NXKySmczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrHNE0zOCCwTR?= MX60PEBp MVHEUXNQ NETMS5lqdmS3Y3XzJGcyKHCqYYPlJINmdGxiY4njcIUh[XK{ZYP0xsA> NXTXRWszOjN6N{eyN|U>
HSC4  MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjGU4YxNTJyIH7N MYW0PEBp MWLEUXNQ NFTsT4ZqdmS3Y3XzJGcyKHCqYYPlJINmdGxiY4njcIUh[XK{ZYP0xsA> NYLk[mhXOjN6N{eyN|U>
HN22 NX;VSmJrTnWwY4Tpc44hSXO|YYm= MlyzNE0zOCCwTR?= MVq0PEBp NX\SS2dWTE2VTx?= NHe4eo5{fXCycnXzd4V{KFOyMTDlfJBz\XO|aX;uxsA> NXr1SYE2OjN6N{eyN|U>
HSC4  NHrGbIVHfW6ldHnvckBCe3OjeR?= MXKwMVIxKG6P M3:xcVQ5KGh? NIKwenlFVVOR NFfVUJJ{fXCycnXzd4V{KFOyMTDlfJBz\XO|aX;uxsA> M2XlVFI{QDd5MkO1
Cal62 NYnmSYNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTN|INMxJFQhdk1? NVu2dFViOjN6MkSwOlQ>
Hth7 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfofWxKSzVyPUG1JOKyKDJibl2= MX:yN|gzPDB4NB?=
Hth83 MoHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLPTWM2OD1|NDFCtUA2KG6P MonLNlM5OjRyNkS=
C643 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2W3bWlEPTB;N{GgxtEhOTBibl2= Mo\0NlM5OjRyNkS=
SW1736 MmLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTN3INMxJFghdk1? NFTyZo8zOzh{NEC2OC=>
T241 M2PETWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;2NotoUUN3ME22OUDDuSB5IH7N M4HIRVI{QDJ2ME[0
T351 NYPpRY5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjoZo9KSzVyPUWwJOKyKDFyIH7N MlLXNlM5OjRyNkS=
BHP2-7 NGjCUI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvsZ5pKSzVyPUO3JOKyKDZibl2= M2ThOFI{QDJ2ME[0
T238 M4HxR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXiTWM2OD1zLEWwNEDDuSB{MECgcm0> NUD0SFc2OjN6MkSwOlQ>
HCT8 M3;HRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnDT3Z{PzJiaB?= MWfEUXNQ NHHsWHpKSzVyPUGyMlnjiIoEsfMAjVEvQSCwTR?= NWnxbXhMOjN{OUmzPFg>
H630 M1fGO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHOfWg4OiCq M1zNcWROW09? MUDJR|UxRTF{LkVihKnDueLCiUOuNUBvVQ>? MWmyN|I6QTN6OB?=
cH630 5-FU-res M2nPcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\mSng4OiCq M4\wOmROW09? NHLwV|NKSzVyPUG1MlXjiIoEsfMAjVEvOiCwTR?= MonPNlMzQTl|OEi=
HCT116 NYPUdGhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fU[VczKGh? MVjEUXNQ M1jwZ2lEPTB;MUCuO-KBkcLz4pEJNk4zKG6P MVqyN|I6QTN6OB?=
HCT116 p53−/− MkDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrM[3I4OiCq MV7EUXNQ NFXnZ5RKSzVyPUiuOwKBkcLz4pEJNU44KG6P MkXGNlMzQTl|OEi=
dHCT116 p21−/− NITOcnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGflTZc4OiCq NVXJboJpTE2VTx?= MonsTWM2OD13LkpihKnDueLCiUGuN{BvVQ>? NUTxcIZbOjN{OUmzPFg>
HT29 M3q3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXSW2lVPzJiaB?= NYS5OYxxTE2VTx?= MVPJR|UxRTF4LkRihKnDueLCiUKuN{BvVQ>? M{\0[|I{Ojl7M{i4
LoVo NEjhXpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXMO|IhcA>? NH\sepJFVVOR NHv4NldKSzVyPUWuNgKBkcLz4pEJNE43KG6P NV3RVpZ2OjN{OUmzPFg>
RKO MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrSVno4OiCq MX\EUXNQ MWDJR|UxRTdwOfMAjeKy6oDLMj6yJI5O M1P1XFI{Ojl7M{i4
SW480 MnfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXi3NkBp MlnvSG1UVw>? NI\xVopKSzVyPUG3MlXjiIoEsfMAjVAvQCCwTR?= NGDDVHgzOzJ7OUO4PC=>
eSW620 NFuySFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVv0U49jPzJiaB?= Mk\JSG1UVw>? NH3nVmRKSzVyPUmuNgKBkcLz4pEJNk4yKG6P NHPHeI0zOzJ7OUO4PC=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
DNMT1 / EZH2; 

PubMed: 19279403     


Western blot of DNMT1 and EZH2 in K562 and LAMA84 following 24 hours treatment with the indicated doses of panobinostat (PS). The levels of β-actin served as the loading control.

caspase-8 / cleaved caspase-8 / Sp1; 

PubMed: 27738323     


The indicated MM cell lines were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of caspase-8, cleaved caspase 8 and Sp1 were analyzed by Western blotting. 

c-Myc / IRF4; 

PubMed: 27738323     


RPMI8226 cells were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of cMyc and IRF4 were analyzed by Western blotting.

Ac-H3 / cleaved caspase-3 / CCND1 / ID1 / ID2 / ID3 / ID4 / Synaptophysin / NeuroD1; 

PubMed: 28915627     


Immunoblotting of whole cell lysates prepared from MB cells treated with panobinostat. The representative western blot result shows panobinostat clearly regulated acetyl-Histone H3 (Ac-H3), cleaved caspase-3, CCND1, IDs, synaptophysin and NeuroD1.

RAD51 / BRCA1 / CHK1 / RPL13a; 

PubMed: 24244429     


CTS, OCI-AML3 or U937 AML cells were treated with variable concentrations of panobinostat for 48 h. Whole cell lysates were subjected to Western blotting to measure protein levels for BRCA1, CHK1, and RAD51 in the cells.

H3K9AC / H3K18AC / H3K56AC / H3 / H4K8AC / H4K16AC / H4 / p21 / p27 / cleaved PARP; 

PubMed: 31071955     


Immunoblot analyses of histone acetylation (H3K9AC, H3K18AC, H3K56AC, H4K8AC and H4K16AC), cell cycle arrest (p27 and p27) and apoptotic-related protein (C-Caspase 3 and C-PARP) expression following various panobinostat treatments for 6 h and 24 h on K562 cells. H3, H4 and GAPDH immunoblots served as internal controls.

19279403 27738323 28915627 24244429 31071955
Immunofluorescence
Synaptophysin / NACM; 

PubMed: 28915627     


Panobinostat treated cells are positive for (B) synaptophysin (red) and (C) NCAM (red). Scale bars, 50 μm.

α-tubulin / Acetyl-α-tubulin; 

PubMed: 29983882     


CLBL-1 cells were treated with 10 nM of panobinostat for 24 h and then microtubules were visualized by immunofluorescence labeling using antibodies against tubulin and acetylated tubulin (ac-tubulin) using the appropriate excitation and emission filters as described in the material and methods section. Representative microphotographs with tubulin and ac-tubulin labeling (green) and DAPI stained-nuclei (blue) at 100× magnification are shown. Scale bar, 5 μm.

BiP; 

PubMed: 23544167     


Immunofluorescence analysis of BiP after 24 and 48 hours of treatment in HepG2 (upper panel) and Hep3B (lower panel) cells with 0.1 µM panobinostat and 10 nM thapsigargin, showing an increase and a different protein distribution in panobinostat-treated cells, comparable to 10 nM thapsigargin effect, used as a positive control. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

ATF4; 

PubMed: 23544167     


HepG2 (left panel) and Hep3B (right panel) cells were treated for 24 and 48 hours with 0.1 µM panobinostat and the immunofluorescence results show an increase of ATF4 and its nuclear localization in both cell lines. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

IRE1α / S724-IRE1α; 

PubMed: 23544167     


Analysis of IRE1α/XBP1 involvement. Immunofluorescence results of IRE1α and its phosphorylated form in HepG2 (A) and Hep3B (B) cell lines after 24 and 48 hours of treatment with 0.1 µM panobinostat. The results indicate that panobinostat induces an increase of both the total and the phosphorylated form of IRE1α and a spotted distribution of this protein (enlargement showed for phospho-IRE1α, B). Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

28915627 29983882 23544167
Growth inhibition assay
Cell viability; 

PubMed: 27738323     


The indicated MM cell lines were cultured in triplicate in the absence or presence of panobinostat at the indicated concentrations. After culturing for 48 hours, cell viability was measured by a WST-8 cell proliferation assay. Results were expressed as the mean +/− SD.

27738323
In vivo In lung cancer and mesothelioma animal models, LBH589 markedly decreases tumor growth by 62%. LBH589 is equally effective in immunocompetent and severe combined immunodeficien-cymice, suggesting that the inhibition of tumor growth by LBH589 is not due to direct immunologic effects. Daily LBH589, given i.p. at 20 mg/kg for 5 days per week, leading to an average decrease in growth of 70%. Compared with the corresponding control tumors, LBH589 leads to a 53% decrease for H526-derived tumors, an 81% decrease for BK-T-derived tumors, a 76% decrease for RG-1- derived tumors, and a 70% decrease for H69-derived tumors. In contrast to the lack of tumor regression notes in NSCLC and Meso-derived xenografted tumors that are treated under identical conditions and doses, LBH589 results in dramatic tumor regression in SCLC-derived tumors and RG-1-derived tumor. [2]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: MOLT-4 cell lines and Reh (pre-B cells)
  • Concentrations: 50 nM
  • Incubation Time: 48 hours
  • Method: Untreated and LBH589-treated cells [human Ph- acute lymphoblastic leukemia MOLT-4 (T cells) and Reh (pre-B cells)] are stained with annexin V and propidium iodide using annexin V-FITC apoptosis detection kit I. The percentage of apoptotic and nonviable cells is determined by flow cytometry. At least 5 × 104 cells are collected with a CyAn ADP Violet cytometer. Percentage apoptosis is calculated considering all the annexin V-positive plus the annexin V/PI-positive cells; percentage loss of cell viability is calculated considering all the annexin V-positive plus the PI-positive and the annexinV/PI-positive cells.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Severe combined immunodeficiency (SCID) mice with M30 (107 cells) or A549 (5 × 106 cells), H69 (2.5 × 106 cells), BK-T (6.5 × 106), H526 (10 × 106), and RG1 (10 × 106) cells
  • Formulation: Dextrose 5% in water
  • Dosages: 10 mg/kg, 20 mg/kg
  • Administration: Administered via i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 69 mg/mL (197.46 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+48% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 349.43
Formula

C21H23N3O2

CAS No. 404950-80-7
Storage powder
in solvent
Synonyms NVP-LBH589

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1
NCT03632317 Recruiting Glioma|Diffuse Intrinsic Pontine Glioma University of Michigan Rogel Cancer Center March 2019 Phase 2
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1
NCT03632317 Recruiting Glioma|Diffuse Intrinsic Pontine Glioma University of Michigan Rogel Cancer Center March 2019 Phase 2
NCT03566199 Recruiting Diffuse Intrinsic Pontine Glioma Sabine Mueller MD PhD|Midatech Pharma US Inc.|Pacific Pediatric Neuro-Oncology Consortium|University of California San Francisco May 22 2018 Phase 1|Phase 2
NCT03566199 Recruiting Diffuse Intrinsic Pontine Glioma Sabine Mueller MD PhD|Midatech Pharma US Inc.|Pacific Pediatric Neuro-Oncology Consortium|University of California San Francisco May 22 2018 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo mice study?

  • Answer:

    We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products5

Tags: buy Panobinostat (LBH589) | Panobinostat (LBH589) supplier | purchase Panobinostat (LBH589) | Panobinostat (LBH589) cost | Panobinostat (LBH589) manufacturer | order Panobinostat (LBH589) | Panobinostat (LBH589) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID